BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33888339)

  • 1. The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Swayze EJ; Strzyzewski L; Avula P; Zebolsky AL; Hoekstra AV
    Gynecol Oncol; 2021 Jun; 161(3):852-857. PubMed ID: 33888339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Weeks K; Lynch CF; West M; Carnahan R; O'Rorke M; Oleson J; McDonald M; Stewart SL; ; Charlton M
    Gynecol Oncol; 2021 Feb; 160(2):477-484. PubMed ID: 33218682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Weeks KS; Lynch CF; West M; Carnahan R; O'Rorke M; Oleson J; McDonald M; Stewart SL; ; Charlton M
    Gynecol Oncol; 2022 Jan; 164(1):3-11. PubMed ID: 34776243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
    Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
    Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes for robotic-assisted laparoscopy versus traditional laparoscopy in clinical stage I epithelial ovarian cancer.
    Facer B; Wang F; Grijalva CG; Alvarez RD; Shu XO
    Am J Obstet Gynecol; 2020 May; 222(5):474.e1-474.e12. PubMed ID: 31715149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
    Knisely A; Huang Y; Melamed A; Tergas AI; St Clair CM; Hou JY; Khoury-Collado F; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Gynecol Oncol; 2020 Aug; 158(2):415-423. PubMed ID: 32456990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.
    Earle CC; Schrag D; Neville BA; Yabroff KR; Topor M; Fahey A; Trimble EL; Bodurka DC; Bristow RE; Carney M; Warren JL
    J Natl Cancer Inst; 2006 Feb; 98(3):172-80. PubMed ID: 16449677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of geography and travel distance on outcomes in epithelial ovarian cancer: a national cancer database analysis.
    Daruvala A; Lucas FL; Sammon J; Darus C; Bradford L
    Int J Gynecol Cancer; 2021 Feb; 31(2):209-214. PubMed ID: 33214215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Surgeon Type and Rurality on Treatment and Survival of Ovarian Cancer Patients.
    Weeks KS; Lynch CF; West MM; Carnahan RM; O'Rorke MA; Oleson JJ; McDonald ME; Charlton ME
    Am J Clin Oncol; 2021 Oct; 44(10):544-551. PubMed ID: 34342289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
    Matsuo K; Huang Y; Zivanovic O; Shimada M; Machida H; Grubbs BH; Roman LD; Wright JD
    Gynecol Oncol; 2019 Sep; 154(3):505-515. PubMed ID: 31279493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.
    Engelen MJ; Kos HE; Willemse PH; Aalders JG; de Vries EG; Schaapveld M; Otter R; van der Zee AG
    Cancer; 2006 Feb; 106(3):589-98. PubMed ID: 16369985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?
    Carney ME; Lancaster JM; Ford C; Tsodikov A; Wiggins CL
    Gynecol Oncol; 2002 Jan; 84(1):36-42. PubMed ID: 11748973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rural residence is related to shorter survival in epithelial ovarian cancer patients.
    Lutgendorf SK; Ramirez E; Schrepf A; Valentine MC; Charlton M; Zimmerman MB; Goodheart MJ; Zia S; Sood AK; Thaker PH
    Gynecol Oncol; 2021 Oct; 163(1):22-28. PubMed ID: 34400004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
    Bouchard-Fortier G; Gien LT; Sutradhar R; Chan WC; Krzyzanowska MK; Liu SL; Ferguson SE
    Gynecol Oncol; 2022 Mar; 164(3):522-528. PubMed ID: 35063277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of lymphadenectomy and survival in epithelial ovarian cancer.
    Ercelep O; Ozcelik M; Gumus M
    Curr Probl Cancer; 2019 Apr; 43(2):151-159. PubMed ID: 30149960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
    Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.
    Lee JY; Kim S; Kim YT; Lim MC; Lee B; Jung KW; Kim JW; Park SY; Won YJ
    BMC Cancer; 2018 May; 18(1):601. PubMed ID: 29843633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Ko EM; Bekelman JE; Hicks-Courant K; Brensinger CM; Kanter GP
    Gynecol Oncol; 2022 Feb; 164(2):295-303. PubMed ID: 34949437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.